Sign In
Buy MIRM
$105.95
-6.64 (-5.90%)
At Close: Jul 31, 2026
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
10:53am, Monday, 17'th Jun 2024
Monday, Mirum Pharmaceuticals Inc. MIRM announced interim results from two Phase 2b studies evaluating volixibat for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).
Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
08:00am, Monday, 17'th Jun 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #pbc--Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:00pm, Monday, 10'th Jun 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
12:36pm, Friday, 07'th Jun 2024
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
04:05pm, Wednesday, 05'th Jun 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months and Older.
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
08:30am, Wednesday, 29'th May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #PFIC--Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress.
Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns
11:06am, Tuesday, 28'th May 2024
Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further.
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript
02:25pm, Saturday, 11'th May 2024
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executi
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30pm, Friday, 10'th May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
12:50pm, Thursday, 09'th May 2024
Mirum's (MIRM) earnings and revenues miss estimates in the first quarter of 2024. Livmarli drives year-over-year sales.
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
04:10pm, Tuesday, 07'th May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference.
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
04:10pm, Wednesday, 01'st May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2024 financial results on May 8, 2024. Mirum will also host a confere
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:06am, Thursday, 25'th Apr 2024
Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
